The relevance of blockading all three pathways was confirmed when inavolisib, a PI3Kα inhibitor, was approved by the FDA as first-line treatment for adults with endocrine-resistant HR+, HER2− advanced breast cancer when combined with palbociclib and fulvestrant based on the favorable results of the INAVO120 trial (10). The gene discussed is HR; the disease is breast carcinoma.